Clinical trials: Percutaneous Coronary Intervention Patients
Patients With a First Acute Myocardial Infarction to be Treated With Primary Percutaneous Coronary Intervention (PCI).
Effect of Additional Treatment With EXenatide in Patients With an Acute Myocardial Infarction (the EXAMI Trial)
Myocardial infarction (MI) causes loss of myocytes and may lead to loss of ventricular function, morbidity and mortality. The most effective therapy is early reperfusion of the ischemic myocardium by percutaneous coronary…
- Trial name
- EXAMI (NCT01254123)
- Testing
- Exenatide infusion
- Where
- Netherlands
- Volunteers
- 40 people
- Sponsor
- Amsterdam UMC, location VUmc
Tricuspid Valve Insufficiency
TRILUMINATE Study With Abbott Transcatheter Clip Repair System in Patients With Moderate or Greater TR
The primary purpose of this study is to evaluate safety and effectiveness of the Tricuspid Valve Repair System (TVRS) for treating symptomatic moderate or greater tricuspid regurgitation (TR) in patients currently on medical…
- Trial name
- TRILUMINATE (NCT03227757)
- Testing
- Tricuspid Valve Repair System
- Where
- 20 sites in United States, France and 4 more
- Volunteers
- 98 people
- Sponsor
- Abbott Medical Devices
Coronary Artery Disease
Comparing Bivalirudin Versus Heparin/ GP IIB/IIA in Patients Undergoing PCI
The purpose of this study is to compare the rates of vascular related complications in patients undergoing percutaneous coronary intervention assigned to one of two arms: 1) bivalirudin + provisional Gp IIB/IIIA use versus 2)…
- Trial name
- NCT00476944
- Testing
- Percutaneous Coronary Intervention (PCI)
- Where
- United States
- Sponsor
- Gold, Herman K., MD
Microvascular Coronary Artery Disease
A Dose Titration Study to Assess the Effects of SAR407899 in Patients With MVA and/or Persistent Stable Angina Despite Angiographically Successful PCI
Primary Objective: To assess the effects of SAR407899 on coronary vasomotor function using the coronary flow reserve (CFR) in participants with microvascular angina (MVA) and/or persistent stable angina despite angiographically…
- Trial name
- NCT03236311
- Testing
- SAR407899, Adenosine, Regadenoson
- Where
- 10 sites in United States, Denmark and 3 more
- Volunteers
- 10 people
- Sponsor
- Sanofi
Myocardial Injury
Cardioprotective Effects of Electroacupuncture Pretreatment Against Coronary Stenting
Myocyte necrosis as a result of elective percutaneous coronary intervention (PCI) occurs in approximately one third of cases and is associated with subsequent cardiovascular events.
- Trial name
- NCT01020942
- Testing
- Electroacupuncture stimulation, No intervention
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Xijing Hospital
Acute Coronary Syndrome
Ticagrelor Versus Clopidogrel in Myocardial Salvage in Patients With STEMI Undergoing Primary PCI
Therefore, in this study, we try to evaluate the impact of clopidogrel loading dose 300mg vs. ticagrelor 180 mg on myocardial injury as measured by contrast-enhanced magnetic resonance imaging (CE-MRI) in STEMI patients…
- Trial name
- NCT02792712
- Testing
- Ticagrelor, Clopidogrel
- Where
- Taiwan
- Volunteers
- 200 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
Coronary Artery Disease
Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI
Two strategies have both proven to be effective in reducing bleeding complications while preserving efficacy compared with maintaining long-term DAPT with aspirin and a potent P2Y12 inhibitor: a) DAPT de-escalation (i.e.…
- Trial name
- TAILOR BLEED (NCT05681702)
- Testing
- aspirin plus clopidogrel, prasugrel or ticagrelor
- Where
- United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- University of Florida
Elective Percutaneous Coronary Intervention, Ischemic Reperfusion Injury
Cardio-protective Effect of Metformin in Patients Undergoing PCI
This is a two-arm randomized parallel study. Patients who will be meeting the above-mentioned criteria and agree to take part in the study, were asked to sign an informed consent prior conducting the study.
- Trial name
- NCT05708053
- Testing
- Metformin
- Where
- 3 sites in Egypt
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Future University in Egypt
Percutaneous Coronary Intervention
Twelve vs 24 Months of Dual Antiplatelet Therapy in Patients With Coronary Revascularization for In-stent Restenosis
Patients undergoing the percutaneous coronary intervention (PCI) for in-stent restenosis (ISR) are enrolled. All patients will be randomized to receive either 12 months or 24 months of dual antiplatelet therapy with a P2Y12…
- Trial name
- NCT02402491
- Testing
- 12 months of P2Y12 receptor antagonist, 24 months of P2Y12 receptor antagonist, Aspirin
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Beijing Anzhen Hospital
High-Risk Percutaneous Coronary Intervention (High-risk PCI), Left Ventricular Assist Devices
Interventional Left Ventricular Assist System for PCI in CHIP Patients
Mechanical circulatory support (MCS) is a life-sustaining therapy first introduced in the 1950s. After six decades of development, it now serves as a critical bridge therapy for patients with acute cardiac events and end-stage…
- Trial name
- NCT07053618
- Testing
- Implantation of the VADLINK Percutaneous Left Ventricular Assist Device, VA-ECMO
- Where
- 15 sites in China
- Volunteers
- 286 people
- Sponsor
- Suzhou Hengruihongyuan Medical Technology Co. LTD
AKI - Acute Kidney Injury
Allopurinol and Trimetazidine as a Preventive of Acute Kidney Injury in PCI Patients
Contrast-associated acute kidney injury (CA-AKI) is a common complication of procedures with intravascular contrast. Generally, CA-AKI is defined as serum creatinine (Scr) ≥ 25 to 50% or Scr rise around 0.3 to 0.5 mg/dl.
- Trial name
- NCT05540184
- Testing
- Trimetazidine 35 mg, Allopurinol 300 MG, Normal saline
- Where
- Egypt
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- Beni-Suef University
Chronic Total Occlusion (CTO)
Feasibility of a Cardiac Rehabilitation Program for CTO Patients Before PCI Treatment
The goal of this clinical trial is to evaluate the feasibility of a cardiac pre-hab program for patients with blocked arteries (CTO) who are referred for PCI treatment.
- Trial name
- PREHAB-CTO (NCT06610708)
- Testing
- Cardiac Prehabilitation Program
- Where
- Canada
- Volunteers
- 70 people
- Sponsor
- Luiz Ybarra
Coronary Disease
Smart Phone Application in the Secondary Clinical Prevention Management for Chinese Patients
The purpose of the study is to investigate the effects of smart phone app on the secondary prevention for patients with coronary heart disease post percutaneous coronary intervention.
- Trial name
- SPASCPM (NCT02847078)
- Testing
- smart phone app, A guideline booklet
- Volunteers
- 86 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
PCI Patients, DAPT(Dual Antiplatelet Therapy)
Comparison of Cardiovascular Risks Between Hip Fracture Surgery With Continued DAPT（Dual Antiplatelet Therapy ） Within 6 Weeks vs After 6 Weeks Post-PCI（Percutaneous Coronary Intervention）: A Prospective Observational Cohort Study
Percutaneous coronary intervention (PCI) is commonly used to treat stable ischemic heart disease. Among patients, 7.5% require surgical treatment, and up to 20% may need noncardiac surgery (NCS) within two years.
- Conditions
- PCI Patients, DAPT(Dual Antiplatelet Therapy), Hip Fracture Surgeries
- Trial name
- NCT07024446
- Testing
- The time interval between PCI and NCS
- Volunteers
- 50 people
- Sponsor
- Fujian Medical University Union Hospital
STEMI - ST Elevation Myocardial Infarction
Correlation Between Triglyceride Glucose Index and Residual SYNTAX Score in STEMI Patients Undergoing PPCI
The goal of this study To check correlation between triglyceride glucose (TyG) index and residual SYNTAX score (RSS) in STEMI patients undergoing PPCI. 2.
- Trial name
- NCT06642259
- Testing
- Echocardiography
- Volunteers
- 185 people
- Sponsor
- Assiut University
Diabetes Mellitus, Percutaneous Coronary Intervention
Intravenous Insulin in Patients With Diabetes After Percutaneous Coronary Intervention (PCI)
The purpose of this study is to evaluate the effects of intravenous insulin/24 hours to normalize glycemia upon markers of oxidative stress (protein oxidation and total antioxidant defense) and inflammation (C-reactive protein…
- Trial name
- NCT00967642
- Testing
- Intravenous Insulin
- Volunteers
- 70 people
- Sponsor
- Hospital de Clinicas de Porto Alegre
Angina Pectoris, Myocardial Infarction
GLP-1 Loading During Elective Percutaneous Coronary Intervention
Angina is caused by narrowings or blockages within coronary arteries. Coronary angioplasty and stenting is performed for people with angina to improve the blood supply to the heart by placing metal tubes within the artery using…
- Conditions
- Angina Pectoris, Myocardial Infarction, Reperfusion Injury, Coronary Heart Disease
- Trial name
- GOLD-PCI (NCT02127996)
- Testing
- GLP-1
- Where
- United Kingdom
- Volunteers
- 193 people
- Sponsor
- Papworth Hospital NHS Foundation Trust
Platelet Reactivity
Prasugrel 5mg Versus High Dose Clopidogrel in Clopidogrel Resistant Patients Aged ≥75 Years and/or Weighing <60 kg Post Percutaneous Coronary Intervention (PCI)
The use of dual antiplatelet therapy is considered standard of care in patients post percutaneous coronary intervention (PCI) with stenting.
- Trial name
- NCT01463150
- Testing
- Clopidogrel, Prasugrel
- Where
- Greece
- Volunteers
- 27 people
- Sponsor
- University of Patras
Coronary Heart Disease, Acute Myocardial Infarction
The Effect of Tongguan Capsule for MicroRNA Profiles in Coronary Heart Disease Patients
The purpose of this study is to test the expression of microRNAs related to the syndromes after the intervention of Tongguan capsule,preliminarily to investigate the mechanism of the effects of Tongguan capsule, and provide the…
- Trial name
- NCT02850627
- Testing
- Tongguan capsule
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Guangdong Provincial Hospital of Traditional Chinese Medicine
Coronary Disease
Reduced Anti-Platelet Therapy With Pimecrolimus Drug Eluting Stent (RAPID)
Non-randomized, single arm, multi-center, clinical trial evaluating the Corio™ pimecrolimus-eluting stent with reduced anti-platelet therapy in patients with de novo lesions of the native coronary arteries.
- Trial name
- NCT00322543
- Testing
- Corio™ Pimecrolimus-eluting stent
- Where
- Brazil
- Volunteers
- 3 people
- Sponsor
- Conor Medsystems